The Neuroprotective Effect of Byu d Mar 25 in LPS-Induced Alzheimer's Disease Mice Model

Figure 3

Light microscopic images show the distribution of p-Tau immunolabeling across the brain of AD + NS, AD + donepezil, and AD + BM25 groups. (a) The distribution of p-Tau immunolabeling in the AD + NS group. (b) The distribution of p-Tau immunolabeling in the AD + donepezil group. (c) The distribution of p-Tau immunolabeling in AD + BM25-L group. (d) The distribution of p-Tau immunolabeling in AD + BM25-M. (e) The distribution of p-Tau immunolabeling in AD + BM25-H. (f) The comparison of p-Tau in AD + NS, AD + donepezil, and AD + BM25 groups. The images revealed that the p-Tau was highly expressed in the AD + NS group compared with the AD + BM25 groups. Data are expressed as the mean ± standard error of the mean (SEM) (n = 8/group in the AD + BM25 group; n = 8/group in the AD + donepezil group; n = 8/group in the AD + NS group). BM25: Byu d Mar 25; AD: Alzheimer’s disease; NS: normal saline.

(a)

(b)

(c)

(d)

(e)

(f)